Table 2

Risk of developing type 2 DM among adolescents and young adults with and without ASD

<18 years18–29 yearsTotal
HR (95% CI)HR (95% CI)HR (95% CI)
ASD, presence vs. absence*2.71 (1.64–4.48)5.31 (2.85–9.90)3.25 (2.23–4.75)
Comorbidities, presence vs. absence
 Hypertension0.79 (0.24–2.69)3.19 (1.71–5.94)2.09 (1.22–3.58)
 Dyslipidemia15.70 (9.15–26.93)9.07 (5.47–15.06)11.11 (7.65–16.13)
 Obesity4.29 (2.28–8.07)2.87 (1.37–6.00)3.46 (2.16–5.53)
Use of atypical antipsychotics
 Nonuser111
 Short-term user1.39 (0.94–3.02)1.74 (0.89–3.42)1.97 (1.20–3.23)
 Long-term user2.35 (1.23–4.50)0.78 (0.39–1.56)1.64 (1.02–2.63)
  • Boldface type indicates statistical significance. *Adjusted for demographic data, use of atypical antipsychotics, and medical comorbidities and ASD as a binary variable.